BNT-314
- Generic Name
- BNT-314
Safety and Preliminary Efficacy of BNT314 with or Without an Immune Checkpoint Inhibitor in Cancer Patients with Malignant Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Malignant Solid Tumor
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 360
- Registration Number
- NCT06150183
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇧🇪GZA Ziekenhuizen, Antwerpen, Belgium
🇧🇪CHU de Liège, Liege, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath